Biotech Startups

Primal Therapies develops microbial biotechnology, including patented small molecule drugs and functional ingredients for biofilm management, infection control, and microbiome modulation. Its SMMRT platform targets metabolic receptors and enzymes in bacteria, viruses, and fungi to address antimicrobial resistance, disinfection, and chronic disease across healthcare and other industries.

1 investor

Primex Pharmaceuticals owns and markets specialty anaesthetic pharmaceuticals for perioperative therapy on a global basis. The company acquires rights to established drug candidates and manages regulatory affairs and distribution without conducting internal R&D or manufacturing.

1 investor

Primient is a producer of food and industrial ingredients derived from plant-based, renewable resources, serving customers in food, beverage, paper, packaging, personal care, apparel, and animal nutrition industries. The company operates production facilities and shared service centers globally, with a focus on sustainable plant-based innovation and bioeconomy solutions.

1 investor

Primitives is a biodesign lab that develops advanced biomaterials—including biopolymers, biominerals, and compostable packaging—aimed at ecosystem regeneration and emissions reduction. Its work spans biodegradable seaweed-based sensors, compostable food packaging that indicates food quality, and MARBLIS, an architectural surfaces brand producing engineered biomarble (biocalcite) from overpopulated or invasive species, serving non-profits, governments, industry, and research organizations.

1 investor

A precision-medicine company that uses radiochemistry and molecular imaging to develop and manufacture radioisotope-based diagnostic and therapeutic drugs, focused on hard-to-treat cancers. It also pursues drug-development partnerships built on its radioisotope platform technology.

1 investor

Primrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.

1 investor

PrintBio manufactures 3D-printed bioresorbable surgical meshes designed for hernia repair and soft tissue support. The company serves surgeons and hospitals seeking customizable mesh solutions that combine stability and flexibility while reducing infection risk.

1 investor

PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.

1 investor

Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.

1 investor

ProAxsis provides biomarker analysis services and research assays for respiratory disease drug development, serving pharmaceutical, biotechnology, and academic research organizations.

1 investor

Procarta Biosystems develops gene control technology to treat drug-resistant bacterial infections, including MRSA. The company was spun out from the John Innes Centre and Plant Biosciences Limited and focuses on anti-infective therapeutics for the biotech and pharmaceutical sector.

1 investor

Procavea Biotech develops a protein-based molecular delivery platform (nonviral protein cages) to address delivery limitations in RNA therapeutics, with applications also in medical imaging. An ETH Zurich spin-off, it targets the pharmaceutical and biotech sector.

1 investor

ProciseDx develops diagnostic technology, including a point-of-care testing platform, drawing on expertise in central lab instrumentation and point-of-care devices. It serves the point-of-care diagnostics market.

1 investor

ProDigest operates advanced in vitro gut simulation platforms that help companies across industries develop superior products. The company specializes in microbial fermentation and gut microbiome research technologies.

1 investor

Profionics develops host-response biomarker technology for rapid detection and diagnosis of sepsis. The company serves healthcare providers and operates in the diagnostic and biotech sectors.

1 investor

Profound Research develops clinical research solutions and decision-support tools for physicians to improve patient access to innovative medical treatments. The company focuses on supporting care delivery decisions that advance medical innovation and patient outcomes.

1 investor

Progentec develops diagnostic and digital health solutions for autoimmune disease detection and treatment, including biomarker tests and remote monitoring technologies for clinicians and patients. The company focuses on improving health outcomes for the 25 million Americans living with autoimmune diseases.

1 investor

Progressive NEURO, Inc. develops medical devices for the treatment of ischemic stroke, including products that go beyond traditional aspiration and thrombectomy to improve first-pass efficacy and reduce distal emboli and vessel wall trauma. The company holds seven issued patents covering five different products.

1 investor

Wyss Zurich is a translational accelerator embedded within ETH Zurich and the University of Zurich, providing funding, infrastructure, technology platforms, and entrepreneurial support to early-stage projects. It focuses on regenerative medicine, robotics, and medical devices/bionics, helping move academic research toward clinical and commercial application.

1 investor

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

1 investor

Prolight Diagnostics develops the Psyros platform, a point-of-care diagnostic system designed to deliver laboratory-quality test results at the patient bedside with speed and cost-effectiveness. The company serves clinical diagnostics markets including traumatic brain injury and cardiac biomarkers.

1 investor

Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.

1 investor

Promed Bioscience develops, manufactures, and supplies highly purified research and medical grade collagen extracted from animal tissue using proprietary methods. It provides collagen-based formulations, biomaterials, and devices customized for research, clinical, and cosmetic/skincare applications, sold through worldwide channels and partners.

1 investor

ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.

1 investor